Drugs facing NCE-1 in 2027

1. List of Aemcolo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263120 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 11 months from now)

US8486446 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 11 months from now)

US8741948 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 11 months from now)

US8529945 REDHILL Oral antimicrobial pharmaceutical compositions
May, 2025

(1 year, 11 months from now)

Do you want to check out AEMCOLO patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 16, 2023
Generating Antibiotic Incentives Now (GAIN) Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 2027-11-17

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

More Information on Dosage

AEMCOLO family patents

10

United States

3

European Union

2

China

2

Canada

2

Japan

2

Korea, Republic of

1

Italy

1

Spain

1

Austria

1

Denmark

1

RS

1

Germany

1

Poland

1

Croatia

1

Cyprus

1

Portugal

1

Mexico

1

South Africa

1

Slovenia

1

Hungary

2. List of Brenzavvy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8802637 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

US7838499 THERACOSBIO Benzylbenzene derivatives and methods of use
Jan, 2029

(5 years from now)

US10981942 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jun, 2031

(8 years from now)

US8987323 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
May, 2032

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021 THERACOSBIO Benzylbenzene derivatives and methods of use
Aug, 2028

(5 years from now)

US10533032 THERACOSBIO Crystalline form of benzylbenzene SGLT2 inhibitor
Jul, 2031

(8 years from now)

Do you want to check out BRENZAVVY patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Daybue drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11370755 ACADIA PHARMS INC Compositions of trofinetide
Aug, 2040

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204 ACADIA PHARMS INC Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid
Jan, 2032

(8 years from now)

Do you want to check out DAYBUE patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2030
New Chemical Entity Exclusivity (NCE) Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

More Information on Dosage

4. List of Filspari drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461 TRAVERE Method for treating disorders associated with glomerular function
Mar, 2030

(6 years from now)

Do you want to check out FILSPARI patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 17, 2030
New Chemical Entity Exclusivity (NCE) Feb 17, 2028

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 2027-02-17

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: TABLET;ORAL

More Information on Dosage

5. List of Jaypirca drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10695323 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10342780 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464905 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

US10918622 LOXO ONCOL Compounds useful as kinase inhibitors
Dec, 2036

(13 years from now)

Do you want to check out JAYPIRCA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 27, 2030
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using PIRTOBRUTINIB ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor

Dosage: TABLET;ORAL

More Information on Dosage

6. List of Jesduvroq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324208 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Dec, 2028

(5 years from now)

US11117871 GLAXOSMITHKLINE Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
Mar, 2038

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557834 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

US8815884 GLAXOSMITHKLINE Prolyl hydroxylase inhibitors
Jun, 2027

(4 years from now)

Do you want to check out JESDUVROQ patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage: TABLET;ORAL

More Information on Dosage

7. List of Joenja drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653092 PHARMING Tetrahydro-pyrido-pyrimidine derivatives
Feb, 2032

(8 years from now)

Do you want to check out JOENJA patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 24, 2030
New Chemical Entity Exclusivity (NCE) Mar 24, 2028

Drugs and Companies using LENIOLISIB PHOSPHATE ingredient

NCE-1 date: 2027-03-25

Market Authorisation Date: 24 March, 2023

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

8. List of Nuzyra drug patents

NUZYRA's oppositions filed in EPO
Can you believe NUZYRA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326696 PARATEK PHARMS INC Amino-methyl substituted tetracycline compounds
Sep, 2023

(3 months from now)

US7553828 PARATEK PHARMS INC 9-aminomethyl substituted minocycline compounds
Jun, 2024

(1 year, 3 days from now)

US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265740 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US10124014 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US9724358 PARATEK PHARMS INC Minocycline compounds and methods of use thereof
Mar, 2029

(5 years from now)

US9314475 PARATEK PHARMS INC Oral and injectable formulations of tetracycline compounds
Mar, 2031

(7 years from now)

US10111890 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and uses thereof
Aug, 2037

(14 years from now)

US10835542 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

US10383884 PARATEK PHARMS INC 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Oct, 2037

(14 years from now)

Do you want to check out NUZYRA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...

Dosage: TABLET;ORAL

More Information on Dosage

NUZYRA family patents

54

United States

22

Japan

17

European Union

14

China

13

Australia

10

Korea, Republic of

9

Canada

9

Taiwan

7

Brazil

6

Spain

6

Denmark

EA

6

EA

6

Croatia

6

Mexico

5

Russia

5

Portugal

5

Slovenia

4

Poland

4

Singapore

4

South Africa

4

Hungary

3

Hong Kong

3

New Zealand

3

Cyprus

3

Lithuania

2

Austria

2

Philippines

2

Czech Republic

2

Morocco

2

Argentina

2

Israel

2

Chile

2

Ecuador

2

Colombia

2

Tunisia

1

Malaysia

1

Turkey

1

Germany

1

Ukraine

1

Norway

9. List of Orserdu drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2023

(6 months from now)

US7612114 STEMLINE THERAP Selective estrogen receptor modulator
Aug, 2026

(3 years from now)

US10385008 STEMLINE THERAP Polymorphic forms of RAD1901-2HCL
Jan, 2038

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071066 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(11 years from now)

US10420734 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(11 years from now)

US10745343 STEMLINE THERAP Polymorphic forms of RAD1901-2HCl
Jan, 2038

(14 years from now)

Do you want to check out ORSERDU patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

10. List of Skyclarys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9670147 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Apr, 2029

(5 years from now)

US8124799 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
Dec, 2029

(6 years from now)

US8993640 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(9 years from now)

US9701709 REATA PHARMS 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
Apr, 2033

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440854 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
Apr, 2029

(5 years from now)

US11091430 REATA PHARMS Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
Apr, 2029

(5 years from now)

Do you want to check out SKYCLARYS patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 28, 2030
New Chemical Entity Exclusivity (NCE) Feb 28, 2028

Drugs and Companies using OMAVELOXOLONE ingredient

NCE-1 date: 2027-02-28

Market Authorisation Date: 28 February, 2023

Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older

Dosage: CAPSULE;ORAL

More Information on Dosage

11. List of Xerava drug patents

XERAVA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10961190 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(14 years from now)

US11578044 TETRAPHASE PHARMS Crystalline forms of eravacycline
Oct, 2037

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Aug, 2029

(6 years from now)

US8906887 TETRAPHASE PHARMS C7-fluoro substituted tetracycline compounds
Dec, 2030

(7 years from now)

Do you want to check out XERAVA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 27, 2023
Generating Antibiotic Incentives Now (GAIN) Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-08-28

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

XERAVA family patents

15

United States

5

Japan

4

China

4

Korea, Republic of

4

European Union

3

Spain

3

Hong Kong

3

Poland

3

Argentina

3

New Zealand

3

Israel

3

Taiwan

2

Denmark

2

RS

2

Singapore

2

Croatia

2

Cyprus

2

Portugal

2

Mexico

2

Slovenia

2

Hungary

1

Philippines

1

Brazil

1

Canada

1

Morocco

1

Norway

1

San Marino

1

Australia

1

Netherlands

1

Colombia

1

Lithuania

1

Luxembourg

12. List of Zavzpret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7220862 PFIZER Calcitonin gene related peptide receptor antagonists
Jan, 2024

(7 months from now)

US8481546 PFIZER CGRP receptor antagonist
Oct, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7314883 PFIZER Anti-migraine treatments
Dec, 2023

(6 months from now)

Do you want to check out ZAVZPRET patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 9, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 2027-03-10

Market Authorisation Date: 09 March, 2023

Treatment: Administration of zavegepant for acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

13. List of Zemdri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US8383596 CIPLA USA Antibacterial aminoglycoside analogs
Jun, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822424 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

US9266919 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(5 years from now)

Do you want to check out ZEMDRI patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 25, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: 2027-06-26

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ZEMDRI family patents

11

United States

2

China

2

Japan

2

European Union

1

Spain

1

Denmark

1

Poland

1

Brazil

1

Canada

EA

1

EA

1

Croatia

1

Korea, Republic of

1

Cyprus

1

Israel

1

Portugal

1

Taiwan

1

Mexico

1

Australia

1

Lithuania

1

Slovenia

1

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in